


# A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models

## SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: SKLB-850 induced tumor cell apoptosis *in vitro*.** (A) Apoptosis of Ramos cells induced by SKLB-850. (B) Apoptosis of HBL-1 cells induced by SKLB-850. Cells were treated vehicle, R788 or indicated concentrations of compounds. After 18 hours, Cells were harvested and stained with Annexin-V-FITC and propidium iodide, then the apoptosis cells were analyzed by FCM.

**Supplementary Table 1: Patient characteristics**

Age	Sex	Disease
66	female	Diffuse small B lymphoma
22	female	follicular lymphoma
47	male	Chronic Lymphocytic Leukemia
40	male	Diffuse large B lymphoma
63	female	Diffuse large B lymphoma